University of Tokyo researchers coated extracellular vesicles with lanthanide ions, making them bind their parent cell type more than 25 times more strongly and opening a route to ultrasensitive liquid biopsies.

Every cell in the body is constantly mailing out tiny parcels. These extracellular vesicles, bubbles of membrane stuffed with proteins and genetic material, drift through blood and other fluids carrying a molecular snapshot of the cell that made them. Cancer cells send them too, which makes vesicles one of the most tantalizing targets in modern diagnostics. The trouble is finding them.

“Each extracellular vesicle is only about a thousandth the width of a human hair and carries a tiny sample of material from the cell that made it like a little molecular ‘message in a bottle,’” said Tianben Ding, an assistant professor in the Department of Chemistry at the University of Tokyo. “Cancer cells release these packages too, but finding them in blood is like searching for a few specific grains of sand on a beach.”

In a study published in Nature Biomedical Engineering, Ding and colleagues in the group of Professor Keisuke Goda report a way to make that search dramatically easier. “So, we developed a simple way to make both the packages and the cancer cells much easier to find,” Ding said.

The problem with looking for cancer in blood

Cancer diagnosis usually still begins with a biopsy, a needle or scalpel removing a piece of suspect tissue. Liquid biopsies, which hunt for traces of a tumor in an ordinary blood draw, promise a gentler and more repeatable alternative that could, in principle, catch disease earlier and track how it responds to treatment. But the signals they chase are vanishingly faint. The release notes that cancer-derived vesicles may number only a few dozen per milliliter of serum, and a single circulating cancer cell may be hidden among billions of healthy blood cells.

Cells, however, have a built-in advantage. Vesicles tend to be taken up preferentially by cells of the same type that released them, a phenomenon called homotypic targeting. The Tokyo team set out to amplify that natural affinity until it became a tool.

Adding extra ‘grips’

Their approach targets sialic acid, a sugar that decorates the surfaces of many cancer cells in unusually high amounts. Lanthanide ions, rare-earth metals such as europium and terbium, bind strongly to that sugar. Coating vesicles with small amounts of these ions gives them a way to latch onto matching cells far more tightly.

“By coating the packages with tiny amounts of lanthanide metals, we made matching packages and cells stick together over 25 times more strongly,” Ding said. The researchers call the effect “super homotypic targeting.”

The gain was not just in strength but in speed. “By decorating extracellular vesicle surfaces with these ions, we effectively added many extra ‘grips,’ so extracellular vesicles and cells of the same lineage bound to one another more strongly and a capture process that used to take more than two days finished in about three hours,” Ding said. The enhanced matching held up even when the engineered vesicles were mixed with billions of vesicles from other cell types.

Ding emphasized that the idea itself is new. “Using a cell’s own vesicles, upgraded with metal ions, as a way to boost recognition between same-type cells is a new concept,” he said. “We’re thrilled that we could turn it into two working diagnostic tools with record-breaking sensitivity, rather than just making a single small improvement.”

Two tools, one platform

The team built two blood tests on the principle and tested them in cultured cells, then in mice, and finally in samples from patients with triple-negative breast cancer, an aggressive form of the disease that lacks the hormone and HER2 receptors targeted by many standard therapies.

The first tool is a detector that uses matched cells to capture a cancer’s vesicles from blood. The second flips the logic: engineered vesicles act as probes that seek out cancer cells themselves, with a signal amplification step that boosts the readout roughly 10,000-fold. According to the release, that makes it possible to spot even a single cancer cell in a relatively large sample using equipment found in a typical laboratory.

Getting there meant solving a classic diagnostic dilemma. “The biggest challenge was achieving both extreme sensitivity and extreme selectivity at the same time,” Ding said. “Cancer signals in blood are hard to detect with just a few dozen extracellular vesicles in a milliliter of serum or a single cancer cell among billions of healthy blood cells.”

Push a test to catch fainter signals and it tends to catch more noise too. “Making a test more sensitive means detecting more false signals too, so we carefully optimized the chemistry to strengthen the binding between matching cells and extracellular vesicles while minimizing unwanted interactions,” Ding explained. “We also developed a way to amplify the signal around 10,000 times, making even a single cancer cell detectable.”

Beyond diagnosis

The researchers frame the work less as a single test than as a general platform for engineering vesicles. “This provides a versatile platform that can improve how engineered extracellular vesicles interact with their target cells,” Ding said, “enabling applications ranging from cancer detection to targeted drug delivery and rejuvenation.” Vesicles that home more reliably to a chosen cell type could, for instance, carry drugs to tumors while sparing healthy tissue.

Important questions remain before any of this reaches a clinic. The release does not report how many mice or patient samples were tested, and the patient work so far focuses on one cancer type. Clinical validation would require far larger studies across many cancers and stages, with careful measurement of false positives and false negatives.

For Ding, though, the consistency across experimental systems was the payoff. “Seeing this work consistently in cultured cells, mice and patient samples made all the effort worthwhile,” he said.

---

Notes

1. “Super homotypic targeting by surface engineering of extracellular vesicles.” Nature Biomedical Engineering, 23 July 2026. DOI: 10.1038/s41551-026-01743-2.
2. University of Tokyo. “Helping cells find their perfect match.” EurekAlert!, 23 July 2026. https://www.eurekalert.org/news-releases/1137493.